- For Patients
- For Physicians
- Our Services
- Contact Information
- Our Providers
- Locations and Hours
- Insurances Accepted
- Hospital Affiliations
Just Some of the Insurances Accepted
Abrazo Health Care
Aetna
AHCCCS
APIPA
Banner
Blue Cross Blue Shield
Cigna
Healthnet
Humana
Medicare
Pacificare
Phoenix Health Plan
United Healthcare
Tricare
Learn more
Conditions We treat
Adult Urology
Prostate Cancer
Erectile Dysfunction
Elevated PSA
Bladder Cancer
BPH/ Enlarged Prostate
Kidney Stones
Urinary Incontinence
Female Organ Prolapse
Infertility/ Vasectomy
Kidney Cancer
Testis Cancer
Hematuria
Recurrent UTIs
Interstial Cystitis
Pediatric Urology
Hypospadias
Undescended Testes
Vesicoureteral Reflux
Pediatric Hernias
UPJ Obstruction
Hydronephrosis
Learn more
Some of the Technologies We Employ
da Vinci Prostatectomy (dVP)
da Vinci Sacrocolpopexy
da Vinci Pyeloplasty
da Vinci Partial Nephrectomy
IGRT/IMRT Radiation Therapy
CT Scan
CT Positron Emission Tomography
Pediatric Diagnostic Ultrasound
GreenLight Laser Vaporization
Diode Laser Vaporization
Prolieve Prostate Microwave
Urologix Prostate Microwave
Interstim
Perigee Pelvic Floor Repair
Elevate Anterior/Posterior Repair
Valley Urologic Associates Welcomes You
Welcome to Valley Urologic Associates, the urology practice of Shawn D. Blick, M.D., Jonathan Agins, M.D., Vi N. Hua, M.D., Rahul Thaly, M.D., Lynn W. Blunt, Jr., M.D., Lipika McCauley, M.D., urologic oncologist Torre H. Rhoades and pediatric urologist Ben O. Donovan, M.D. Our urologists practice in Goodyear, Glendale and Phoenix, Arizona. Our urologists combine extensive experience and the latest technological advances in addressing urological concerns. Our urologists and staff partner with patients in the treatment of adult and pediatric urological disease. We strive to offer treatment that is state of the art with compassion and sensitivity. Our urologists are trained at the World's foremost institutions and are adept in all areas of urology, including Fellowship Trained specialization to address specific areas of urology such as da Vinci robotic surgery, urologic oncology, and pediatric urology.
- VUA Welcomes Dr. Lipika McCauley, M.D.We would like to announce the addition of Dr. McCauley to VUA. She is well trained in all areas of Urology from the University of Arizona in Tucson. She is currently accepting patients at the Paradise Valley and Arrowhead locations.
- USPSTF Issues Grade D for PSA screening sends the wrong message.The US Preventitive Services Task Force (USPSTF) issues a grade of D for using PSA in screeing for prostate cancer. To abolish the PSA level for screening would regress back to digital rectal exams prior to the PSA era. SEER survival statistics from the National Cancer Institute Table 23.9 shows a clear survival benefit in early detection. The PSA test was accepted as a screening tool around 1990, beginning the PSA era. The survival rates for prostate cancer patients has dramatically reached upwards of 99% in the last decade. The American Urologic Association issues a strong opposition to the USPSTF recommendation and is gathering a panel of experts to submit comments to the USPSTF.Learn more from our latest Newsletter.
- FDA Issued Advisory on Transvaginal Mesh Repair for Pelvic Organ Prolapse and Related ComplicationsThe FDA recently issued an advisory on using transvaginal mesh to repair pelvic organ prolapse due to a perceived increase in complications. As an expert in pelvic floor reconstruction and a valued leader in the field, Dr. Shawn Blick recognizes the events that have led to the FDA's report, and he agrees with many of the points covered in the FDA's Safety Communication. However, Dr. Blick strongly believes that the recent FDA UPDATE fails to convey an accurate perspective to the public, to the press, and unfortunately, to the legal community. He also feels that several key conclusions in the UPDATE are not consistent with the scientific literature pertaining to vaginal mesh and are inconsistent with the clinical realities that we encounter as surgeons caring for women with severe prolapse and incontinence.
- FDA Issues Reccomendations on Actos to Patients with Bladder CancerThe FDA issues a drug update in regards to ongoing post market research. The five-year results showed that although there was no overall increased risk of bladder cancer with pioglitazone use, an increased risk of bladder cancer was noted among patients with the longest exposure to pioglitazone, and in those exposed to the highest cumulative dose of pioglitazone.
FDA is also aware of a recent epidemiological study conducted in France which suggests an increased risk of bladder cancer with pioglitazone. Based on the results of this study, France has suspended the use of pioglitazone and Germany has recommended not to start pioglitazone in new patients.
FDA recommends that healthcare professionals should:
Not use pioglitazone in patients with active bladder cancer.
Use pioglitazone with caution in patients with a prior history of bladder cancer. The benefits of blood sugar control with pioglitazone should be weighed against the unknown risks for cancer recurrence.
- Read Our Latest NewsletterWe have put together a periodic newsletter for our referring physicians and our dedicated patients. Please look inside for valuable information...Learn more
- Saturday Clinics! Due to increased patient demand, we have some clinics open on Saturdays to accomodate our new patients. Please call to see if there is an appointment open to see one of our physicians.
VUA Offices
West Valley Office
13555 W. McDowell Road
Suite 304
Goodyear, AZ 85395
Arrowhead Office
18699 N. 67th Avenue
Suite 230
Glendale, AZ 85308
Paradise Valley Office
3815
E. Bell Road
Suite 3600
Phoenix, AZ 85032
VUA Team
If you are having trouble seeing this site, download the latest browser or if you have a problem seeing the Flash content, download the latest Adobe flash plugin.